Summary & Overview
CPT 84681: C–Peptide Laboratory Assay, Technical Component
CPT code 84681 designates the laboratory measurement of C–peptide, a marker produced alongside insulin that helps distinguish endogenous insulin production from exogenous insulin use. Nationally, this assay is important for evaluating diabetes type differentiation, assessing residual beta-cell function, and informing management of hypoglycemia and insulin therapy. The test is commonly ordered in outpatient and inpatient clinical laboratory settings and is performed by trained lab analysts.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for C–peptide testing, typical sites of service, common billing considerations, and which payers commonly cover laboratory services of this type. The publication summarizes available benchmarks, common modifier usage, and notable policy elements when present.
This summary provides context for clinicians, laboratory administrators, and billing professionals seeking a concise reference on CPT code 84681, its clinical relevance, and payer landscape. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 84681 describes a laboratory test measuring C–peptide, the peptide fragment produced when the pancreas secretes insulin. The procedure represents the technical component of the assay performed by the lab analyst to quantify C–peptide levels in a patient sample.
Service type: Laboratory — clinical chemistry/diagnostic assay
Typical site of service: Clinical laboratory or hospital laboratory
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with suspected endogenous insulin dysregulation who presents to an outpatient endocrinology clinic for evaluation of hypoglycemia or poor glycemic control. The clinician orders a C‑peptide blood test to distinguish between endogenous insulin production and exogenous insulin administration. The workflow: the clinician documents the indication (for example, recurrent unexplained hypoglycemia or assessment of endogenous insulin in type 1 versus type 2 diabetes), places a lab order for C‑peptide (technical component billed with 84681), the patient has a peripheral venous blood draw in the clinic or outpatient laboratory, the specimen is sent to the clinical laboratory, a laboratory technologist performs the analytic assay and reports a numeric result with reference range, and the ordering clinician reviews the result and documents interpretation and plan in the medical record. Typical sites of service include outpatient hospital laboratories, independent clinical laboratories, and hospital ambulatory clinic phlebotomy units. Typical clinical modifiers that may apply include those reflecting professional/technical components, emergency department origin, or specimen handling nuances, as well as standard billing modifiers for multiple or staged procedures.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 |